The present invention relates to a compound represented by the following General Formula (1) or a salt thereof.

##STR00001##

In General Formula (1), R.sup.1, R.sup.2, R.sup.3 and R.sup.4 each independently represent a hydrogen atom, a linear or branched alkyl group which may have a substituent or the like. R.sup.1 and R.sup.2 may be bonded to each other to form a ring. R.sup.3 and R.sup.4 may be bonded to each other to form a ring. R.sup.1 and/or R.sup.2 may be bonded to a 6-membered ring to which —NR.sup.1R.sup.2 is bonded to form a ring. R.sup.3 and/or R.sup.4 may be bonded to a 6-membered ring to which —NR.sup.3R.sup.4 is bonded to form a ring. R.sup.5 represents —.sup.11CH.sub.3, a linear or branched alkyl group which may have a substituent or the like. R.sup.6 represents —F, —.sup.18F or the like. X, Y and Z each independently represent a carbon atom, an oxygen atom or the like. n is 0 or 1.

The present disclosure includes in one aspect substituted arylmethyl ureas, substituted heteroarylmethyl ureas, or analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.

The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.

The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.

Quinolines, polyquinolines, polybenzoquinolines, molecular segments of fullerenes and graphene nanoribbons, and graphene nanoribbons and processes for producing such materials are provided. The processes utilize a form of an aza-Diels-Alder (Povarov) reaction to first form quinolines and/or polyquinolines. In some such embodiments polyquinolines thus produced are used to form graphene nanoribbon precursors, and molecular segments and graphene nanoribbons. In many such embodiments the graphene nanoribbon precursors are formed from polybenzoquinolines.

The present invention relates to an anti-SARS-CoV-2 drug including, as an active ingredient, a compound represented by formula (I):

##STR00001##

[wherein R.sup.1 is C.sub.1-C.sub.8 alkyl or the like; and R.sup.2-R.sup.9 is hydrogen, halogen, hydroxyl, or Q-(C.sub.1-C.sub.8 alkyl), (Q is O, NH, or S) or the like], or a pharmaceutically acceptable salt thereof.

The present invention relates to an anti-SARS-CoV-2 drug including, as an active ingredient, a compound represented by formula (I):

##STR00001##

[wherein R.sup.1 is C.sub.1-C.sub.8 alkyl or the like; and R.sup.2-R.sup.9 is hydrogen, halogen, hydroxyl, or Q-(C.sub.1-C.sub.8 alkyl), (Q is O, NH, or S) or the like], or a pharmaceutically acceptable salt thereof.

The present application relates to a polycyclic compound including nitrogen and an organic light emitting device including the same.

An improved process for obtaining at least one bis-benzyl isoquinoline alkaloid from botanical material involves contacting the botanical material with a supercritical fluid having as a major component one or more aliphatic hydrocarbon compounds, such as alkanes, alkenes, cyclic aliphatic hydrocarbons, or a combination of these compounds.

An improved process for obtaining at least one bis-benzyl isoquinoline alkaloid from botanical material involves contacting the botanical material with a supercritical fluid having as a major component one or more aliphatic hydrocarbon compounds, such as alkanes, alkenes, cyclic aliphatic hydrocarbons, or a combination of these compounds.